Our top pharmaceutical stocks to buy are all expected to have double-digit gains, making now a great time to buy.
With new drugs on the market, these companies have revenue coming in to fund pipeline developments. These pipeline developments will fuel revenue growth for years to come.
One of the stocks on our list is expected to gain as much as 172% in the next 12 months...
Johnson & Johnson news sees two analysts bringing down JNJ stock by more than 1% in the past five trading days.
The pullback comes after the stock was downgraded by both analysts last Friday, but we still consider the stock a buy since it is so undervalued.
And if you buy the stock buy Aug. 25, you get an automatic 2.57% in additional gains...
These five pharmaceutical penny stocks to watch for August 2017 have made gains of as much as 50% in the last 30 days.
But don't let these gains fool you. They may not last long, since penny stock share prices are so volatile.
Start the conversation
Leave a Reply
This pharmaceutical stock to buy is undervalued compared to its peers.
A big reason why this stock is undervalued is that analysts don't look at the whole company to determine its worth and therefore discount their target prices for the company.
And while Wall Street is missing out on a great deal, you don't have to...
Start the conversation
Leave a Reply
The pharmaceutical industry is expected to see spending in the sector double in the next few years.
The best pharmaceutical stock in 2017 is set to cash in on the increased spending by taking advantage of the medical marijuana trends.
And it could potentially gain 100% to double your money in the next 12 months...
Despite the recent negative news, Insys Therapeutics stock is still a great buy.
Even better for investors is the fact that it has an upcoming catalyst that is going to send the price per share soaring.
Our expert has developed a vetting process to identify the best pharmaceutical stocks to buy in 2017.
One of the stocks he picked using this set of guidelines is already up almost 60% year to date.
Here are the guidelines and the best stocks to buy now for major profits this year...
The pharma sector has widely outperformed the broader market lately.
That's why we've made this list of the 10 top pharmaceutical stocks to watch in May 2017.
We're also including our pick for one of the best pharma stocks to buy this year. Check it out...
Start the conversation
Leave a Reply
The Mylan scandal and the Clinton Foundation have a damning connection involving shoddy drug practices.
This just-released report contains all the evidence...
Markets have no memory. So once again they are rallying based on false hopes that central bankers will save them from themselves.
Despite a stealth bear market in many stocks, the major indices have recovered all of their 2015 losses in October. They've been boosted by several factors - large cap tech stocks, expectations for a delay in Fed tightening, more European QE, and further interest rate cuts by an increasingly desperate China...Such are the stuff that dreams are made of in the terminal stages of one of the biggest bull markets in history.
As I've written before, I believe that bull market is over and we are now likely entering a bear market. There are too many macroeconomic headwinds to sustain further stock market gains.
The Chinese economic miracle is over. Commodity prices are not going to recover any time soon...
Start the conversation
Leave a Reply
Pharmaceutical companies have been raising the price of prescription drugs at an alarming rate since 2010.
According to a new report from The Wall Street Journal, the 30 highest-selling drugs in the United States saw their prices increase roughly 76% from 2010 through 2014.
And as they've raised prices, their profits have soared...
Start the conversation
Leave a Reply
Another possible deal between two of the world's top pharmaceutical companies was announced this week when Shire Plc. (Nasdaq: SHPG) made an unsolicited offer of $30.6 billion for Baxalta Inc. (NYSE: BXLT).
Money Morning Defense & Tech Specialist Michael A. Robinson has been following this trend since 2014. He knew the world's top pharmaceutical companies would continue their M&A binge, and he recommended an investment to play that wave.
Robinson's pick has already climbed 17.6% this year and still has plenty of room to run...
Start the conversation
Leave a Reply
Pharmaceutical stocks have crushed the broader markets in 2015.
The S&P Pharmaceuticals Select Industry Index has climbed 20.9% year to date. In the last 12 months, the index has climbed 42.5%.
Here's how that compares to the broader markets...
Start the conversation
Leave a Reply
Prescription drug spending continues to hit record highs, and the world's top pharma companies continue to bank billions.
More than $374 billion was spent on prescription drugs in the United States in 2014, according to a report from the IMS Institute of Health. That was a 13.1% jump from 2013, and the highest growth rate in more than a decade, says ExpressScripts.
Here's a look at how U.S. prescription drug spending has trended over the last 10 years..
The world's top pharma companies bring in billions in revenue every year, sometimes from only a few products.
That's the case with each of these top pharma companies. This chart shows the most expensive prescription drugs in the world. The most expensive drug, Soliris, costs each patient $409,500 every year.
Here are the seven most expensive drugs in the world:
Start the conversation
Leave a Reply
Two top pharmaceutical companies announced a merger this morning, continuing 2015's massive run of M&A activity.
Botox maker Allergan Plc. (NYSE: AGN) announced today that it will purchase Kythera Biopharmaceuticals Inc. (Nasdaq: KYTH) for $2.1 billion. That values KYTH shares at $75 each - 24% higher than Tuesday's closing price.
Start the conversation